228 related articles for article (PubMed ID: 32179032)
1. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
4. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
5. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
6. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
8. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Nam JM; Robyn J; Loberiza F; Maciejewski JP; Simonis T; Molldrem J; Young NS; Barrett AJ
Blood; 2002 Sep; 100(5):1570-4. PubMed ID: 12176872
[TBL] [Abstract][Full Text] [Related]
9. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract][Full Text] [Related]
10. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
[TBL] [Abstract][Full Text] [Related]
11. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
[TBL] [Abstract][Full Text] [Related]
13.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
14. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
[TBL] [Abstract][Full Text] [Related]
16. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; de Witte T; Neukirchen J; Sekeres MA; Brunner AM; Roboz GJ; Steensma DP; Bhatt VR; Platzbecker U; Cluzeau T; Prata PH; Itzykson R; Fenaux P; Fathi AT; Smith A; Germing U; Ritchie EK; Verma V; Nazha A; Maciejewski JP; Podoltsev NA; Prebet T; Santini V; Gore SD; Komrokji RS; Zeidan AM
Blood Adv; 2018 Jul; 2(14):1765-1772. PubMed ID: 30037803
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
19. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
20. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
